ARRIVE II CONFIRMS LOW TAXUS-RELATED RE-INTERVENTION RATE

Preliminary six-month results from the ARRIVE II registry confirm the safety of the TAXUS Express2 coronary stent system in real patients, Boston Scientific announced.

ARRIVE II expands on the ARRIVE I registry by studying more than 5,000 consecutively enrolled patients across 53 sites in the U.S., including patients with complex lesions (65 percent), multiple stents (38 percent) and diabetes (32 percent).

The ARRIVE II registry completed enrollment in October 2005 with a total of 5,007 patients. Preliminary clinical findings were collected for the first 4,057 patients (81 percent) enrolled through May 2005. Complete six-month data on all patients will be available in May 2006.